PROCEPT BioRobotics Corporation, a surgical robotics company, develops transformative solutions in urology. It develops, manufactures, and sells AquaBeam Robotic System, an image-guided, surgical robotic system for use in minimally-invasive urologic surgery with a focus on treating benign prostatic hyperplasia (BPH). The company also designs Aquablation therapy for males suffering from lower urinary tract symptoms due to BPH. PROCEPT BioRobotics Corporation was incorporated in 2007 and is headquartered in Redwood City, California.
IPO Year: 2021
Exchange: NASDAQ
Website: procept-biorobotics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 12/2/2024 | $105.00 | Overweight | Morgan Stanley |
| 11/14/2024 | $95.00 | Hold | Jefferies |
| 8/11/2023 | $42.00 | Overweight | Piper Sandler |
| 5/31/2023 | Outperform | William Blair | |
| 10/31/2022 | Neutral | BTIG Research | |
| 10/25/2022 | $58.00 | Buy | Truist |
| 9/2/2022 | $49.00 | Overweight | Wells Fargo |
| 7/15/2022 | $47.00 | Overweight | KeyBanc Capital Markets |
| 6/23/2022 | $53.00 | Buy | B. Riley Securities |
| 3/9/2022 | $48.00 → $42.00 | Buy | B of A Securities |
Morgan Stanley initiated coverage of PROCEPT BioRobotics with a rating of Overweight and set a new price target of $105.00
Jefferies initiated coverage of PROCEPT BioRobotics with a rating of Hold and set a new price target of $95.00
Piper Sandler initiated coverage of PROCEPT BioRobotics with a rating of Overweight and set a new price target of $42.00
William Blair initiated coverage of PROCEPT BioRobotics with a rating of Outperform
BTIG Research initiated coverage of PROCEPT BioRobotics with a rating of Neutral
Truist initiated coverage of PROCEPT BioRobotics with a rating of Buy and set a new price target of $58.00
Wells Fargo initiated coverage of PROCEPT BioRobotics with a rating of Overweight and set a new price target of $49.00
KeyBanc Capital Markets initiated coverage of PROCEPT BioRobotics with a rating of Overweight and set a new price target of $47.00
B. Riley Securities initiated coverage of PROCEPT BioRobotics with a rating of Buy and set a new price target of $53.00
B of A Securities reiterated coverage of PROCEPT BioRobotics with a rating of Buy and set a new price target of $42.00 from $48.00 previously